Arne Solberg - Concepedia

Concepedia

Author

Arne Solberg

St Olav's University Hospital

Also Known As

Arne O. Solberg, Arne Solberg, Solberg, Arne

48

Publications

2.7K

Citations

17

H-Index

36

Concepts

All Affiliations

St Olav's University Hospital Oslo University Hospital Norwegian University of Science and Technology Ålesund Hospital University of Oslo

AS

About

Arne Solberg is an author at St Olav's University Hospital specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.7K
2	Health Sciences	3	3	172
3	Obstetrics	2	2	33
4	Diagnostic Sciences	1	1	41
5	Endocrinology	1	1	863

Arne Solberg

×

25

Publications

2.7K

Citations

17

H-Index

	Year	Citations
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Anders Widmark, Olbjørn Klepp, Arne Solberg, The Lancet Endocrine OncologyUrologyRadiation MedicineMedicineEndocrine Treatment	2008	863
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial Oliver Sartor, Robert L. Coleman, Sten Nilsson, The Lancet Oncology UrologyOncologyMedicinePharmacotherapyCastration-resistant Prostate Cancer	2014	485
Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program Torgrim Tandstad, Olav Dahl, Gabriella Cohn‐Cedermark, Journal of Clinical Oncology	2009	262
Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group Torgrim Tandstad, Rune Smaaland, Arne Solberg, Journal of Clinical Oncology	2011	230
Frequency of Lymphoceles after Open and Laparoscopic Pelvic Lymph Node Dissection in Patients with Prostate Cancer Arne Solberg, Anders Angelsen, Unni Bergan, Scandinavian Journal of Urology and Nephrology	2003	118
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial Christopher Parker, Robert E. Coleman, Oliver Sartor, European Urology	2017	103
Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Chris Parker, Daniel Heinrich, Joe M. O’Sullivan, Journal of Clinical Oncology Radium-223 ChloridePharmacotherapyOsteoporosisTreatment VerificationInflammatory Arthritis	2012	98
Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7 Sophie D. Fosså, Fredrik Wiklund, Olbjørn Klepp, European Urology Nonmetastatic Locally AdvancedUrologyGenitourinary CancerMedicineBrachytherapy	2016	87
Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group Sven-Erik Olofsson, Torgrim Tandstad, Mats Jerkeman, Journal of Clinical Oncology	2011	67
Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor Øivind Kvammen, Tor Åge Myklebust, Arne Solberg, Cancer Epidemiology Biomarkers & Prevention	2016	66

Page 1